Echeazu Ogu
Dr. Echeazu Ogu is a Pharmaceutical Scientist and Independent Consultant with deep experience in Quality Assurance, Quality Control, Clinical and Non-Clinical Development, and Regulation of medicinal products. He has contributed to the Regulatory approval of 10+ medicines for the US and worldwide markets [including Sustiva® and Stockrin® (Efavirenz) for HIV/AIDS]. From 2008 – 2016, Dr. Ogu served on several US Federal Panels that reviewed proposals received in response to NIH RFP solicitations, enabling award of contracts worth hundreds of millions of dollars. He has served as a Consultant, Advisor, Problem solver, and Trainer for industry, and Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC); and was appointed to the Nigerian Clinical Trials Technical Working Group. Previously, Dr Ogu held Senior Positions in R&D, Quality, and Corporate Oversight at Lavipharm Laboratories, Bristol Myers Squibb (DuPont Merck Pharmaceuticals), Bayer (Monsanto Company), Pfizer and others. He holds a PhD Degree in Analytical Chemistry from Saint Louis University, St Louis, MO.